[
  {
    "question": "The preferred daily controller therapy for GINA Step 2 asthma in adults is?",
    "options": {
      "A": "SABA PRN",
      "B": "Low-dose inhaled corticosteroid",
      "C": "Oral corticosteroid",
      "D": "Leukotriene modifier PRN"
    },
    "correctAnswer": "B",
    "topic": "asthma_management",
    "deepDiveExplanation": "According to GINA guidelines, Step 2 asthma is characterized by symptoms occurring more than twice a month but less than daily. The preferred daily controller therapy for this step is a low-dose inhaled corticosteroid (ICS). While GINA 2023 also offers low-dose ICS-formoterol PRN as a preferred reliever for Step 1 and Step 2, a daily controller remains a cornerstone for persistent asthma.",
    "highYieldPearl": "Low-dose ICS is the foundational controller for persistent asthma, starting from GINA Step 2.",
    "examStyle": "NEET-SS",
    "difficulty": "Easy",
    "trapAnalysis": "Option A (SABA PRN) is for Step 1 (intermittent asthma) or as a reliever. Options C and D are not initial daily controllers for Step 2.",
    "isOneLiner": true,
    "id": "one_liner_one-liner|asthma_management|Asthma - Management and Step Therapy|10_olmsjwkp"
  },
  {
    "question": "Which drug class is the preferred reliever medication for all adult asthma severity levels according to GINA 2023?",
    "options": {
      "A": "SABA",
      "B": "Inhaled Corticosteroid-Formoterol",
      "C": "Oral Corticosteroid",
      "D": "Tiotropium"
    },
    "correctAnswer": "B",
    "topic": "asthma_management",
    "deepDiveExplanation": "GINA 2023 guidelines emphasize a 'preventer-reliever' approach. The preferred reliever for all adult asthma severity levels (Steps 1-5) is low-dose inhaled corticosteroid-formoterol PRN. This strategy ensures that even with reliever use, patients receive some anti-inflammatory benefit, reducing the risk of exacerbations compared to SABA monotherapy.",
    "highYieldPearl": "GINA 2023 recommends low-dose ICS-formoterol as the preferred reliever for all asthma steps in adults, replacing SABA monotherapy in most cases.",
    "examStyle": "NEET-SS",
    "difficulty": "Medium",
    "trapAnalysis": "SABA (Option A) was historically the preferred reliever but is now considered less preferred due to its lack of anti-inflammatory action and potential for adverse outcomes with overuse. Options C and D are not primary reliever medications.",
    "isOneLiner": true,
    "id": "one_liner_one-liner|asthma_management|Asthma - Management and Step Therapy|10_m6eru6ax"
  },
  {
    "question": "The mechanism of action of Omalizumab in severe allergic asthma involves targeting which molecule?",
    "options": {
      "A": "IL-5",
      "B": "IgE",
      "C": "IL-4/IL-13",
      "D": "TSLP"
    },
    "correctAnswer": "B",
    "topic": "asthma_management",
    "deepDiveExplanation": "Omalizumab is a humanized monoclonal antibody that selectively binds to free circulating immunoglobulin E (IgE), preventing it from binding to mast cells and basophils. This reduces the release of inflammatory mediators and is effective in severe allergic asthma.",
    "highYieldPearl": "Omalizumab specifically targets IgE, making it suitable for severe allergic asthma.",
    "examStyle": "NEET-SS",
    "difficulty": "Easy",
    "trapAnalysis": "Other biologics target different pathways: Mepolizumab, Reslizumab, Benralizumab target IL-5 or its receptor (Option A). Dupilumab targets IL-4/IL-13 (Option C). Tezepelumab targets TSLP (Option D).",
    "isOneLiner": true,
    "id": "one_liner_one-liner|asthma_management|Asthma - Management and Step Therapy|10_d3ktt0ky"
  },
  {
    "question": "Which biologic agent targets the IL-5 pathway for severe eosinophilic asthma?",
    "options": {
      "A": "Omalizumab",
      "B": "Dupilumab",
      "C": "Mepolizumab",
      "D": "Tezepelumab"
    },
    "correctAnswer": "C",
    "topic": "asthma_management",
    "deepDiveExplanation": "Mepolizumab (anti-IL-5), Reslizumab (anti-IL-5), and Benralizumab (anti-IL-5R) are monoclonal antibodies specifically approved for severe eosinophilic asthma. They work by blocking the IL-5 cytokine or its receptor, thereby reducing eosinophil production and survival.",
    "highYieldPearl": "Think 'Mepolizumab, Reslizumab, Benralizumab' for IL-5 targeting in eosinophilic asthma.",
    "examStyle": "NEET-SS",
    "difficulty": "Medium",
    "trapAnalysis": "Omalizumab targets IgE. Dupilumab targets IL-4/IL-13. Tezepelumab targets TSLP. All are biologics for asthma but have different mechanisms.",
    "isOneLiner": true,
    "id": "one_liner_one-liner|asthma_management|Asthma - Management and Step Therapy|10_tg78jfuy"
  },
  {
    "question": "What is the critical threshold for SABA use frequency suggesting inadequate asthma control and need for step-up?",
    "options": {
      "A": "Less than 2 times/month",
      "B": "More than 2 times/week",
      "C": "More than 4 times/month",
      "D": "Daily use"
    },
    "correctAnswer": "B",
    "topic": "asthma_management",
    "deepDiveExplanation": "According to GINA guidelines, asthma is considered 'uncontrolled' if a patient experiences daytime symptoms more than twice a week, has any night waking due to asthma, requires reliever medication more than twice a week (excluding pre-exercise SABA), or has any activity limitation due to asthma. Frequent SABA use (>2 times/week) is a key indicator for stepping up controller therapy.",
    "highYieldPearl": "SABA use >2 times/week indicates uncontrolled asthma and warrants a step-up in controller therapy.",
    "examStyle": "NEET-SS",
    "difficulty": "Easy",
    "trapAnalysis": "The 'more than twice a week' rule is a fundamental criterion for assessing asthma control and the need for adjustment in therapy. Other options are either too infrequent or too frequent to be the specific threshold for 'step-up'.",
    "isOneLiner": true,
    "id": "one_liner_one-liner|asthma_management|Asthma - Management and Step Therapy|10_h3kkl91e"
  },
  {
    "question": "Which medication class is primarily indicated as an add-on therapy for asthma patients with aspirin-exacerbated respiratory disease?",
    "options": {
      "A": "LABA",
      "B": "LAMA",
      "C": "LTRA",
      "D": "Theophylline"
    },
    "correctAnswer": "C",
    "topic": "asthma_management",
    "deepDiveExplanation": "Leukotriene receptor antagonists (LTRAs) are particularly useful in patients with aspirin-exacerbated respiratory disease (AERD), also known as Samter's Triad. These patients have an overproduction of leukotrienes, which LTRAs effectively block, leading to symptom improvement.",
    "highYieldPearl": "LTRAs are a specific add-on for AERD due to their anti-leukotriene effect.",
    "examStyle": "NEET-SS",
    "difficulty": "Medium",
    "trapAnalysis": "LABAs (long-acting beta-agonists), LAMAs (long-acting muscarinic antagonists), and Theophylline are general add-on therapies for asthma but do not have this specific indication for AERD.",
    "isOneLiner": true,
    "id": "one_liner_one-liner|asthma_management|Asthma - Management and Step Therapy|10_pjcro43w"
  },
  {
    "question": "The primary indication for initiating maintenance oral corticosteroids in severe asthma is?",
    "options": {
      "A": "Frequent exacerbations despite high-dose ICS/LABA",
      "B": "Eosinophilic phenotype",
      "C": "Allergic rhinitis co-morbidity",
      "D": "Patient preference"
    },
    "correctAnswer": "A",
    "topic": "asthma_management",
    "deepDiveExplanation": "Maintenance oral corticosteroids (OCS) are reserved for the most severe, uncontrolled asthma cases (GINA Step 5) where symptoms and exacerbations persist despite optimal high-dose inhaled corticosteroid (ICS) and long-acting beta-agonist (LABA) therapy, and often after trials of other add-on therapies like LAMAs or biologics. Chronic OCS use carries significant side effects, so it is a last resort.",
    "highYieldPearl": "Maintenance OCS is a last-line therapy for severe asthma uncontrolled by all other options, due to significant side effects.",
    "examStyle": "NEET-SS",
    "difficulty": "Medium",
    "trapAnalysis": "While an eosinophilic phenotype (Option B) might guide biologic choice, it's not the direct indication for maintenance OCS. Allergic rhinitis (Option C) is a comorbidity, not a reason for maintenance OCS. Patient preference (Option D) is never a primary clinical indication for such a potent medication.",
    "isOneLiner": true,
    "id": "one_liner_one-liner|asthma_management|Asthma - Management and Step Therapy|10_ialvrls1"
  },
  {
    "question": "Which inhaled corticosteroid is typically combined with formoterol for GINA 'maintenance and reliever therapy' (MART)?",
    "options": {
      "A": "Budesonide",
      "B": "Fluticasone",
      "C": "Beclomethasone",
      "D": "Ciclesonide"
    },
    "correctAnswer": "A",
    "topic": "asthma_management",
    "deepDiveExplanation": "Budesonide-formoterol is the classic and most extensively studied combination for Maintenance And Reliever Therapy (MART) in asthma. Formoterol's rapid onset of action makes it suitable for both maintenance and quick relief when combined with an ICS like budesonide.",
    "highYieldPearl": "Budesonide-formoterol is the quintessential MART combination due to formoterol's rapid onset.",
    "examStyle": "NEET-SS",
    "difficulty": "Medium",
    "trapAnalysis": "While fluticasone (Option B) is a common ICS, it is typically combined with slower-onset LABAs like salmeterol or vilanterol, not formoterol for MART. Beclomethasone and Ciclesonide are also ICS but not typically used in MART combinations with formoterol.",
    "isOneLiner": true,
    "id": "one_liner_one-liner|asthma_management|Asthma - Management and Step Therapy|10_kha4u2ay"
  },
  {
    "question": "The recommended strategy for stepping down asthma treatment after at least three months of good control is?",
    "options": {
      "A": "Abruptly stop all medications",
      "B": "Reduce ICS dose by 25-50%",
      "C": "Increase SABA use",
      "D": "Discontinue LABA first"
    },
    "correctAnswer": "B",
    "topic": "asthma_management",
    "deepDiveExplanation": "Once asthma is well-controlled for at least 3 months, a step-down approach should be considered to find the minimum effective dose. The recommended strategy is to gradually reduce the inhaled corticosteroid (ICS) dose by 25-50% at 3-month intervals, while continuing to monitor control. Abrupt cessation or discontinuing LABA first (without adjusting ICS) is not recommended.",
    "highYieldPearl": "Step down asthma therapy gradually by reducing the ICS dose after 3 months of good control.",
    "examStyle": "NEET-SS",
    "difficulty": "Easy",
    "trapAnalysis": "Options A and D are potentially dangerous as they can lead to loss of control or exacerbations. Option C (increasing SABA use) is the opposite of stepping down controller therapy.",
    "isOneLiner": true,
    "id": "one_liner_one-liner|asthma_management|Asthma - Management and Step Therapy|10_xmptc4m1"
  },
  {
    "question": "Which anticholinergic agent is approved as an add-on therapy for severe asthma in adults?",
    "options": {
      "A": "Ipratropium bromide",
      "B": "Tiotropium bromide",
      "C": "Glycopyrronium",
      "D": "Aclidinium"
    },
    "correctAnswer": "B",
    "topic": "asthma_management",
    "deepDiveExplanation": "Tiotropium bromide, a long-acting muscarinic antagonist (LAMA), is approved as an add-on therapy for severe asthma in adults and adolescents (â‰¥12 years) who remain symptomatic despite high-dose ICS/LABA. It provides additional bronchodilation and may reduce exacerbations.",
    "highYieldPearl": "Tiotropium is the specific LAMA approved for add-on therapy in severe asthma.",
    "examStyle": "NEET-SS",
    "difficulty": "Easy",
    "trapAnalysis": "Ipratropium bromide (Option A) is a short-acting anticholinergic for acute relief. Glycopyrronium and Aclidinium (Options C and D) are also LAMAs but are primarily approved for COPD, not severe asthma in this context.",
    "isOneLiner": true,
    "id": "one_liner_one-liner|asthma_management|Asthma - Management and Step Therapy|10_9t6634nb"
  }
]